Literature DB >> 21882091

Determination of the cutoff level of apparent diffusion coefficient values for detection of prostate cancer.

Masako Nagayama1, Yuji Watanabe, Akito Terai, Tohru Araki, Kenji Notohara, Akira Okumura, Yoshiki Amoh, Takayoshi Ishimori, Satoru Nakashita, Yoshihiro Dodo.   

Abstract

PURPOSE: The aim of this study was to determine the cutoff level of apparent diffusion coefficient (ADC) values for diagnosing prostate cancer.
MATERIALS AND METHODS: A total of 45 consecutive patients with prostate cancer who underwent diffusion-weighted magnetic resonance imaging (MRI) with ADC maps before radical prostatectomy were included in this retrospective study. MRI findings were correlated retrospectively with histopathological results of surgical specimens. Comparisons of ADC values between cancer and noncancer areas were performed with the two-tailed unequal variance t-test. The cutoff ADC level was determined in a way to achieve the best accuracy for detecting prostate cancer.
RESULTS: The mean ADC value of all the cancer lesions (n =60) was 1.04 ± 0.31 (×10(-3) mm(2)/s). In the peripheral zone, the mean ADC values of cancer lesions and noncancer areas were 1.07 ± 0.35 and 1.94 ± 0.31, respectively (P < 0.001). In the transition zone, the mean ADC values of cancer lesions and noncancer areas were 1.00 ± 0.22 and 1.56 ± 0.14, respectively (P<0.001). The cutoff level for the ADC value was determined to be 1.35×10(-3) mm(2)/s. It provided sensitivity, specificity, and accuracy of 88%, 96%, and 93%, respectively.
CONCLUSION: The cutoff ADC level determined on the basis of the results obtained from radical prostatectomy specimens can help differentiate malignant from nonmalignant lesions.

Entities:  

Mesh:

Year:  2011        PMID: 21882091     DOI: 10.1007/s11604-011-0586-6

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  38 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization.

Authors:  Jeong Kon Kim; Seong Sook Hong; Young Jun Choi; Seong Ho Park; Hanjong Ahn; Choung-Soo Kim; Kyoung-Sik Cho
Journal:  J Magn Reson Imaging       Date:  2005-11       Impact factor: 4.813

3.  Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate.

Authors:  Chiho Sato; Shinji Naganawa; Tatsuya Nakamura; Hisashi Kumada; Shunichi Miura; Osamu Takizawa; Takeo Ishigaki
Journal:  J Magn Reson Imaging       Date:  2005-03       Impact factor: 4.813

4.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging.

Authors:  Oguz Akin; Evis Sala; Chaya S Moskowitz; Kentaro Kuroiwa; Nicole M Ishill; Darko Pucar; Peter T Scardino; Hedvig Hricak
Journal:  Radiology       Date:  2006-03-28       Impact factor: 11.105

5.  In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging.

Authors:  Bashar Issa
Journal:  J Magn Reson Imaging       Date:  2002-08       Impact factor: 4.813

6.  Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue.

Authors:  Keyanoosh Hosseinzadeh; Samuel David Schwarz
Journal:  J Magn Reson Imaging       Date:  2004-10       Impact factor: 4.813

7.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Akira Yamamoto; Takenori Yamashita; Naoto Egashira; Shigeki Imai; Masao Fukunaga
Journal:  Radiology       Date:  2008-06-06       Impact factor: 11.105

Review 8.  Imaging prostate cancer: a multidisciplinary perspective.

Authors:  Hedvig Hricak; Peter L Choyke; Steven C Eberhardt; Steven A Leibel; Peter T Scardino
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

9.  High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio.

Authors:  Kazuhiro Kitajima; Yasushi Kaji; Kagayaki Kuroda; Kazuro Sugimura
Journal:  Magn Reson Med Sci       Date:  2008       Impact factor: 2.471

10.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Authors:  Deanna L Langer; Theodorus H van der Kwast; Andrew J Evans; Laibao Sun; Martin J Yaffe; John Trachtenberg; Masoom A Haider
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

View more
  11 in total

1.  Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.

Authors:  Tan B Nguyen; Alexander Ushinsky; Albert Yang; Michael Nguyentat; Sara Fardin; Edward Uchio; Chandana Lall; Thomas Lee; Roozbeh Houshyar
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

Review 2.  Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.

Authors:  Durgesh Kumar Dwivedi; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2022-07-22       Impact factor: 2.533

3.  Role of diffusion-weighted imaging in differentiating benign and malignant pediatric abdominal tumors.

Authors:  Rakhee S Gawande; Gabriel Gonzalez; Solomon Messing; Aman Khurana; Heike E Daldrup-Link
Journal:  Pediatr Radiol       Date:  2013-05-12

4.  Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters.

Authors:  S F Riches; G S Payne; V A Morgan; D Dearnaley; S Morgan; M Partridge; N Livni; C Ogden; N M deSouza
Journal:  Eur Radiol       Date:  2015-03-07       Impact factor: 5.315

5.  Prostate cancer GTV delineation with biparametric MRI and 68Ga-PSMA-PET: comparison of expert contours and semi-automated methods.

Authors:  Nathan Hearn; John Blazak; Philip Vivian; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2021-01-28       Impact factor: 3.039

6.  Targeted biopsy based on ADC map in the detection and localization of prostate cancer: a feasibility study.

Authors:  Yuji Watanabe; Masako Nagayama; Tohru Araki; Akito Terai; Akira Okumura; Yoshiki Amoh; Takayoshi Ishimori; Satoru Nakashita; Yoshihiro Dodo
Journal:  J Magn Reson Imaging       Date:  2012-11-16       Impact factor: 4.813

7.  Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC map: a prospective large-scale cohort study.

Authors:  Yuji Watanabe; Akito Terai; Tohru Araki; Masako Nagayama; Akira Okumura; Yoshiki Amoh; Takayoshi Ishimori; Mana Ishibashi; Satoru Nakashita; Yoshihiro Dodo
Journal:  J Magn Reson Imaging       Date:  2012-01-13       Impact factor: 4.813

Review 8.  The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.

Authors:  Chen Jie; Liu Rongbo; Tan Ping
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

Review 9.  Diagnostic accuracy of DWI in patients with ovarian cancer: A meta-analysis.

Authors:  Xia Yuan; Linghong Guo; Wei Du; Fei Mo; Ming Liu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

10.  Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness.

Authors:  Andrei Lebovici; Silviu A Sfrangeu; Diana Feier; Cosmin Caraiani; Ciprian Lucan; Mihai Suciu; Florin Elec; Gheorghita Iacob; Mircea Buruian
Journal:  BMC Med Imaging       Date:  2014-05-10       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.